Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Capital Market

10.04USD
3:59pm EST
Change (% chg)

$-0.18 (-1.76%)
Prev Close
$10.22
Open
$10.10
Day's High
$10.14
Day's Low
$10.01
Volume
12,575
Avg. Vol
17,235
52-wk High
$16.36
52-wk Low
$8.10

RDHL.OQ

Chart for RDHL.OQ

About

RedHill Biopharma Ltd. is a biopharmaceutical company focused on the development and acquisition of late clinical-stage, orally administered drugs for the treatment of inflammatory and gastrointestinal diseases, and cancer. The Company's products pipeline includes RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA (ABC294640), MESUPRON,... (more)

Overall

No Ratios Available.

Financials

  RDHL.OQ Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -- -- --
ROI: -- -1.38 14.86
ROE: -- -1.07 16.28

BRIEF-Redhill Biopharma provides 2017 semi-annual business update

* Re-submission of Rizaport NDA to FDA is expected in first half of 2017

Jan 12 2017

BRIEF-Redhill Biopharma announces QIDP fast-track designation granted by FDA to RHB-104 for nontuberculous mycobacteria infections

* Redhill Biopharma announces QIDP fast-track designation granted by FDA to RHB-104 for nontuberculous mycobacteria infections

Jan 11 2017

BRIEF-EMC2 Fund Ltd reports 11.87 percent passive stake in RedHill Biopharma Ltd as of Dec 27, 2016 - SEC filing

* EMC2 Fund Ltd reports 11.87 percent passive stake in RedHill Biopharma Ltd as of Dec 27, 2016 - SEC filing Source text: (http://bit.ly/2hZ6g81) Further company coverage:

Jan 06 2017

BRIEF-Redhill Biopharma reports qtrly loss per ordinary share $0.07

* Redhill biopharma reports 2016 third quarter financial results Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Redhill Biopharma reports positive FDA type B meeting on RHB-105

* Redhill biopharma ltd says confirmatory phase iii study with rhb-105 for h. Pylori infection is planned to be initiated in h1/2017

Nov 10 2016

BRIEF-RedHill Biopharma provides update on ongoing phase III, phase II studies with Bekinda

* RedHill Biopharma Ltd - top-line results from both studies are expected in mid-2017

Nov 03 2016

BRIEF-Redhill Biopharma announces proposed public offering of its American Depository Shares

* Redhill Biopharma Ltd says intends to use proceeds from offering to fund clinical development programs

Nov 01 2016

BRIEF-Redhill Biopharma to allow multiple sclerosis patent in Japan

* Redhill Biopharma announces allowance of a patent in Japan supporting RHB-104 for multiple sclerosis

Oct 18 2016

BRIEF-Redhill Biopharma provides progress update on RHB-104 Phase III crohn's disease program

* Redhill Biopharma provides progress update on RHB104 Phase III crohn's disease program and introduces option for early stop for success in Q2/2017

Oct 06 2016

BRIEF-Redhill Biopharma Ltd and IntelGenx announce RIZAPORT commercialization with pharmatronic co.

* Redhill Biopharma and IntelGenx announce RIZAPORT commercialization term sheet with Pharmatronic Co. for Korea

Sep 21 2016

Earnings vs. Estimates